

## Special Issue

# Personalized Radiotherapy for Improved Clinical Benefit

### Message from the Guest Editor

Radiotherapy is a medical procedure forming part of the overall therapeutic strategy discussed at a multidisciplinary panel with an optimal goal of locally curing tumors and protecting, as best as possible, the surrounding normal tissues. The use of personalized treatments is increasing in radiation oncology, including technical aspects, biological biomarkers, new combinations with innovative drugs, new dosimetric approaches, and so on. In this Special Issue of *Cancers*, we welcome original research articles or comprehensive review articles focusing on the development of any aspects of personalizing radiotherapy (normal tissues or tumors) biomarkers in relation to radiobiology, new technologies to better target the tumors and protect surrounding healthy tissues, new dosimetric aspects, or any innovations to improve clinical benefit using ionizing radiations. I hope that this collection of studies will further increase our knowledge on personalized radiotherapy and provide powerful tools to fight against cancer.

### Guest Editor

Prof. Dr. David Azria

Montpellier Cancer Institute (ICM), University of Montpellier,  
Montpellier, France

### Deadline for manuscript submissions

closed (20 August 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/150965](https://mdpi.com/si/150965)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)